NCT02798224 is a NA clinical trial of e-assist: Colon Health in Colorectal Cancer, sponsored by UNC Lineberger Comprehensive Cancer Center.

Who is sponsoring NCT02798224?

NCT02798224 is sponsored by UNC Lineberger Comprehensive Cancer Center.

What drugs are being tested in NCT02798224?

Interventions in NCT02798224: e-assist: Colon Health, Healthwise Educational Program.

What condition does NCT02798224 study?

NCT02798224 studies Colorectal Cancer.

Is NCT02798224 still recruiting?

NCT02798224 is currently completed. Last updated 25 October 2022.

Last reviewed 2022-10-25 · How we verify

NCT02798224

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Patient Portal Tool, E-assist, for Supporting CRC Screening

Completed NA Last updated 25 October 2022

What this trial tests

NA trial testing e-assist: Colon Health in Colorectal Cancer in 1,826 participants. Completed in 27 July 2021.

Timeline

14 June 2017

Primary endpoint
25 September 2020

27 July 2021

Quick facts

Lead sponsor	UNC Lineberger Comprehensive Cancer Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	health services research
Enrollment	1,826
Start date	14 June 2017
Primary completion	25 September 2020
Estimated completion	27 July 2021
Sites	1 location across United States

Drugs / interventions tested

e-assist: Colon Health
Healthwise Educational Program

Conditions studied

Colorectal Cancer — all drugs for Colorectal Cancer →

Sponsor

UNC Lineberger Comprehensive Cancer Center — full company profile →

Who can join

Adults 50 to 75, any sex, with Colorectal Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To compare patient perceptions, intent to screen, and screening use among those using a patient portal with and without a colorectal cancer (CRC) screening decision support tool, e-assist. To evaluate whether the effectiveness of e-assist is moderated by multi-level factors, including patient health literacy, decision-making preference, and CRC screening decision stage. To assess program impact and create an implementation guide for e-assist by combining results from Aims 1 \& 2, a program implementation analysis/process evaluation and the perspectives of staff from future diverse implementation sites including small primary care practices, University-based primary practices and federally-qualified health centers.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Patient-Reported Needs Following a Referral for Colorectal Cancer Screening.
Dyer KE, Shires DA, Flocke SA, Hawley ST, et al · · 2019 · cited 12× · PMID 30554975 · DOI 10.1016/j.amepre.2018.08.017
Randomised trial to evaluate the effectiveness and impact of offering postvisit decision support and assistance in obtaining physician-recommended colorectal cancer screening: the e-assist: Colon Health study-a protocol study.
Lafata JE, Shin Y, Flocke SA, Hawley ST, et al · · 2019 · cited 6× · PMID 30617102 · DOI 10.1136/bmjopen-2018-023986

Verify or expand the search:

Other recruiting trials for Colorectal Cancer

Currently open trials in the same condition.

NCT07152821 — Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcino · Phase 3 · recruiting
NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
NCT07432633 — [18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications · Phase 1, PHASE2 · recruiting
NCT07523919 — Functional and Respiratory Determinants of Long-Term Colorectal Cancer Outcomes · recruiting
NCT07529301 — Functional and Respiratory Predictors of Early Postoperative Outcomes · recruiting

Other UNC Lineberger Comprehensive Cancer Center trials

Trials by the same sponsor.

NCT06656936 — The PharmFIT Study · NA · not yet recruiting
NCT05937659 — Incorporating Biometric Data for Patients Receiving Concurrent Chemotherapy & RT · not yet recruiting
NCT07479199 — Local Radiofrequency Ablation Plus External Beam Radiation for the Treatment of Painful Thoracic and Lumbar Spine Tumors · not yet recruiting
NCT07069595 — PREDICT-RD: ctDNA Surveillance in TNBC With Residual Disease · Phase 2 · recruiting
NCT04266730 — Trial of a Personalized and Adaptive Neoantigen Dose-Adjusted Vaccine Concurrently With Pembrolizumab · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02798224 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by UNC Lineberger Comprehensive Cancer Center
Last refreshed: 25 October 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02798224.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing